Brinckerhoff Quoted on ACLU/Myriad Decision

14 June 2013 Financial Times News

Financial Times

Partner Courtenay Brinckerhoff was quoted in a June 14, 2013 Financial Times article titled, “Agricultural groups explore impact of ruling.” The article discussed the implications of the Supreme Court’s June 13, 2013 decision in the “ACLU/Myriad” gene patenting case (12-398, Association for Molecular Pathology v. Myriad Genetics, Inc.) on agricultural biotech companies. Manufacturers of GM seeds and altered plant material had thought themselves beyond the reach of Myriad, because they “believe their products have been changed enough to fall outside the judges’ definition of ‘products of nature.’” However, Ms. Brinckerhoff cautioned that, in light of Myriad and other recent decisions, companies should be proactive in reviewing patent portfolios as well as their legal position, and be prepared to take on new competitors. She stated, “It’s never crystal clear until you have the actual same facts decided.”

Related Services

Insights

RCE PTA Carve-Out Resumes After Interference
18 September 2019
PharmaPatents
The Ninth Circuit Expected to Rule that Doctors Can Be Wrong in the Winter v. Gardens False Claims Act Case
18 September 2019
Legal News: Government Enforcement Defense & Investigations
Upcoming Webinar: Maximizing Solar Tax Credits - Navigating the Start of Construction Rules (Part 1)
17 September 2019
Renewable Energy Outlook
When Birds Finally Find a Nest
17 September 2019
Dashboard Insights
MedTech Impact Expo & Conference
13-15 December 2019
Las Vegas, NV
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
BRG Healthcare Leadership Conference
06 December 2019
Washington, D.C.
CTeL Telehealth Fall Summit 2019
04-06 December 2019
Washington, D.C.